Moderna, Inc.

NASDAQ:MRNA

Biotechnology

Healthcare
$196.79 +4.01%

+$2.48 today

Market cap
$79.63B
Beta
1.03
P/E (TTM)
-7.9
EPS (TTM)
-$8.09
52W Low $22.28High $67.74

Volume 6.91M

Average 6.53M

MRNA Interest Income

Income earned on cash, deposits, and investments held by the company.

Moderna, Inc.NASDAQ: MRNA

Interest Income · Q3 FY2026 · quarter ended Sep 2026

Interest income declines year over year

Q3 FY2026 interest income of $62M fell 15.1% year over year, ahead of the -19.1% change in trailing-twelve-month interest income. Sequentially, it fell 7.5% from the prior quarter. Over 3 fiscal years it compounded at +16.2% a year.

Context

  • Interest income amounted to 16.2% of revenue in FY2025, up 2.9 pp from a year earlier.
  • Interest income increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -15.1% holds above the trailing-twelve-month pace of -19.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$62M-7.5% QoQ
Last fiscal yearDec 2025
$314M-26.1% YoY
LTMSep 2026
$271M-19.1% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-15.1%——
1 year-26.1%——
3-year CAGR+16.2%——
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
314M USD
Year-over-year change
-26.1%
4-year CAGR
+104.4%

Interest Income vs competitors

How MRNA compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -19.1% is the 5th highest of 8, against a peer median of -15.9%.
  • Interest income amounts to 10.7% of revenue for MRNA, versus a peer median of 1.2%.
MRNA Competitors
Interest Income for MRNA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$553.61M USD+13486.2%-20.3%—
PFEPfizer Inc.LTM Jun 2026$532M USD-9.1%+33.9%0.8%
BNTXBioNTech SELTM Jun 2026€420.15M EUR—+74.6%15.9%
MRNAModerna, Inc.LTM Sep 2026$271M USD-19.1%+16.2%10.7%
PCVXVaxcyte, Inc.LTM Jun 2026$108.08M USD-15.9%+142.9%—
GSKGSK plcLTM Jun 2026£106M GBP+24.7%-4.5%0.3%
VIRVir Biotechnology, Inc.LTM Mar 2026$35.14M USD-44.1%+12.7%53.7%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$9.27M USD-47.9%+57.6%20.4%
VALNValneva SELTM Mar 2026€1.89M EUR-27.6%+90.7%1.2%
NVAXNovavax, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding MRNA) —-15.9%+45.7%1.2%

Competitors are the stored peer set for MRNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue17.74B18.88B6.85B3.2B1.94B
Cost of Revenue2.62B5.42B4.69B1.46B868M
Gross Profit15.12B13.46B2.16B1.74B1.08B
Gross Margin85.2%71.3%31.5%54.2%55.3%
Research & Development1.99B3.3B4.85B4.54B3.13B
Selling, General & Admin567M1.13B1.55B1.17B1.02B
Operating Expenses1.82B4.04B6.39B5.68B4.15B
Depreciation & Amortization232M348M621M189M215M
EBITDA13.54B9.95B(3.28B)(3.39B)(2.55B)
EBITDA Margin76.3%52.7%-47.9%-106.1%-131.3%
Operating Income13.3B9.42B(4.24B)(3.95B)(3.07B)
Operating Margin75.0%49.9%-61.9%-123.3%-158.1%
Interest Income18M200M421M425M314M
Interest Expense18M29M38M24M10M
Other Income / Expenses(11M)155M297M338M306M
Income Before Tax13.29B9.58B(3.94B)(3.61B)(2.77B)
Pre-Tax Margin74.9%50.7%-57.6%-112.8%-142.4%
Income Tax Expense1.08B1.21B772M(46M)54M
Net Income12.2B8.36B(4.71B)(3.56B)(2.82B)
Net Margin68.8%44.3%-68.8%-111.3%-145.2%
EPS (Basic)30.3121.26(12.34)(9.27)(7.26)
EPS (Diluted)28.2920.10(12.34)(9.27)(7.26)
Weighted Avg Shares403M394M382M384M389M
Weighted Avg Shares (Diluted)431M416M382M384M389M

Moderna, Inc.

NASDAQ:MRNA

Intrinsic Alpha fair value

Locked

Current Price

$196.79

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.